The Evolution of Antibody–Drug Conjugates in Breast Cancer

Review this comprehensive program including an on-demand Webcast and downloadable slidesets from a symposium at EBCC 2020 to gain expert perspectives on how to apply new ADCs in breast cancer as well as on new data and promising agents that may soon change practice.

Share

Program Content

Activities

T-DM1 in BC
T-DM1: Setting the Stage for ADC Development in Breast Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 30, 2020

Next-Gen ADCs in BC
Next-Generation HER2-Directed ADCs in Development
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 30, 2020

New ADCs: HER2 and Beyond
ADCs with Alternative HER2 Targeting Mechanisms and Beyond HER2-Positive Disease: Expanding Potential Benefit to Other Breast Cancer Subsets
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 30, 2020

<i>EP</i>: ADC in BC
ExpressPoints: The Evolution of Antibody–Drug Conjugates in Breast Cancer
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: November 03, 2020

Activities

ADCs in Breast Cancer
The Evolution of Antibody–Drug Conjugates in Breast Cancer
Congratulations: You achieved a completion on 04/09/2022

Faculty

cover img faculity

Prof Michael Untch, MD, PhD

Director of the Clinic
Gynecology, Gyencologic Oncology and Obstetrics
Helios Hospital Berlin-Buch
Berlin, Germany

cover img faculity

Javier Cortes, MD, PhD

Head, Breast Cancer Program
IOB Institute of Oncology
Madrid and Barcelona, Spain

cover img faculity

Ian E. Krop, MD, PhD

Associate Professor of Medicine
Harvard Medical School
Associate Chief, Division of Breast Oncology
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.